ReviewAnnals of translational medicine2021
Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results.
Review in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Myasthenia Gravis and Thymoma.Muscle & nerve · 2026Review
- Hyperthermic intrathoracic chemotherapy in the management of pleural malignancies: current evidence, limitations, and future directions.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2026Article
- Advanced thymic epithelial tumours after neoadjuvant therapy: a narrative review of surgical challenges and strategies.Mediastinum (Hong Kong, China) · 2026Review
- Stage IVa thymoma: optimizing surgical management according to anatomical boundaries of the pleural space.Mediastinum (Hong Kong, China) · 2026Article
- Robotic Resection With Hyperthermic Intrathoracic Perfusion Chemotherapy for Thymoma Recurrence.Case reports in oncological medicine · 2026Article
- Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases.Oncology · 2026Article
- Applying expertise: Extrapleural pneumonectomy and extended pleurectomy decortication in the management of Masaoka-Koga stage IV thymoma.JTCVS open · 2025Article
- Hyperthermic intrathoracic chemotherapy (HITHOC) in stage IVA thymomas: a narrative review.Mediastinum (Hong Kong, China) · 2025Review
- Article
- Review
- Successful Implementation of HITOC and HIPEC in the Management of Advanced Ovarian Carcinoma with Pleural and Peritoneal Carcinomatosis.Diagnostics (Basel, Switzerland) · 2024Article
- Li-Fraumeni Syndrome With Six Primary Tumors-Case Report.Case reports in oncological medicine · 2024Article
- The valuable role of extended pleurectomy decortication and HITHOC for disseminated pleural thymoma.Mediastinum (Hong Kong, China) · 2024Article
- Hyperthermic intrapleural chemotherapy: an update.Journal of thoracic disease · 2023Review
- Article
- Outcomes of extended surgical resections for locally advanced thymic malignancies: a narrative review.Gland surgery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWith this narrative review, we retraced the history of hypertermic intrathoracic chemotherapy (HITHOC) since the beginning, analyzing literature on operative technique, feasibility and efficacy of this treatment. Moreover, we report the fifteen-year experience of our center in this relatively new technique, for what concerns both early postoperative results and long-term oncological outcomes.
backgroundThymomas are frequently misdiagnosed and recognized in advanced stage, often with pleural dissemination, especially when not associated to Myasthenia Gravis that allows an early diagnosis during the initial assessment. Moreover, the natural history of locally advanced thymoma is characterized by a high rate of pleural or pericardial relapses. Surgery has always been considered a milestone in thymoma's treatment, even in case of serous dissemination or relapses, although his role as exclusive therapy does not guarantee an acceptable local disease control. In case of disseminated disease, different multidisciplinary protocols have been experimented, from chemotherapy to radiation therapy, alone or associated to surgery, in order to increase overall and disease-free survival, but the breakthrough happened in the early 90s with the introduction of HITHOC following surgery. Combination of surgery and HITHOC resulted in less toxic than systemic chemotherapy and providing a good local disease control in patients with stage IVa thymomas or thymoma's pleural recurrences.
methodsWe searched PubMed for relevant literature, up to January 2020, on hypertermic intrapleural chemotherapy for thymomas (TPR or DNT), selecting only those reporting information about HITHOC protocol used, postoperative course and oncological outcomes.
conclusionsHITHOC is a safe and feasible procedure, with a very low complication rate and negligible systemic effects of chemotherapeutic agents, effective in controlling both TPR and DNT, in particular as regards local disease-free survival. KEYWORDS: Hypertermic intrathoracic chemotherapy (HITHOC); thymoma; intracavitary chemotherapy; hyperthermia; redo-surgery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.